Follow-up Letter to the HHS OIG Calling for Probe of Acting FDA Commissioner Woodcock’s Role in FDA’s Inappropriately Close Collaboration With Biogen

View as PDF

View press release

Following Acting Food and Drug Administration (FDA) Commissioner Janet Woodcock’s July 9 belated request to the Department of Health and Human Services (HHS) Office of Inspector General to investigate the “interactions between Biogen and the FDA during the process leading to the decision to approve” aducanumab for treatment of Alzheimer’s disease, Public Citizen urged the OIG to examine Dr. Woodcock’s role in the unprecedented, inappropriately close collaboration between the FDA and Biogen before and after the submission of the company’s marketing application for the drug.

July 20, 2021, response letter from the HHS Officer of Inspector General.

See Public Citizen’s other work on aducanumab.